These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33637618)

  • 1. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial.
    Wu Z; Zhao J; Lam W; Yang M; Chen L; Huang X; Wei M; Yang H; Lv F; Zhang F; Zeng J; Zhang GM
    Br J Ophthalmol; 2022 Jul; 106(7):975-979. PubMed ID: 33637618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
    Jin E; Yin H; Li X; Zhao M
    Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
    Zhang H; Yang X; Zheng F; Wan S; Xu Y
    Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.
    Zhang G; Yang M; Zeng J; Vakros G; Su K; Chen M; Li H; Tian R; Li N; Tang S; He H; Tan W; Song X; Zhuang R;
    Retina; 2017 Apr; 37(4):710-717. PubMed ID: 27529839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
    Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
    BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity.
    Bai Y; Nie H; Wei S; Lu X; Ke X; Ouyang X; Feng S
    Br J Ophthalmol; 2019 Apr; 103(4):494-498. PubMed ID: 30030391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
    Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
    Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.
    Wu L; Li M; Wang L; Yan H; Zhou Z; Fan J; Zhou Y; Gou K; Guo C; Wang Y; Zhang Z
    Sci Rep; 2023 Nov; 13(1):19946. PubMed ID: 37968276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
    Chuluunbat T; Chan RV; Wang NK; Lien R; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Ophthalmic Surg Lasers Imaging Retina; 2016 Dec; 47(12):1095-1105. PubMed ID: 27977832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity.
    Cheng Y; Sun S; Deng X; Zhu X; Linghu D; Sun X; Liang J
    Br J Ophthalmol; 2022 Sep; 106(9):1295-1300. PubMed ID: 33836990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity.
    Jin E; Yin H; Gui Y; Chen J; Zhang J; Liang J; Li XX; Zhao M
    J Ophthalmol; 2019; 2019():3935945. PubMed ID: 31976086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.